V501 Phase II Immunogenicity Study in Females Aged 9 to 17 Years
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors Banyu; Merck & Co; Merck Sharp & Dohme
- 17 Dec 2009 Actual patient number (100) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual end date (Sept 2009 ) added as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.